Frans Erdkamp

7.3k total citations · 2 hit papers
82 papers, 3.7k citations indexed

About

Frans Erdkamp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Frans Erdkamp has authored 82 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 27 papers in Cancer Research. Recurrent topics in Frans Erdkamp's work include Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (20 papers) and Advanced Breast Cancer Therapies (19 papers). Frans Erdkamp is often cited by papers focused on Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (20 papers) and Advanced Breast Cancer Therapies (19 papers). Frans Erdkamp collaborates with scholars based in Netherlands, United States and United Kingdom. Frans Erdkamp's co-authors include Miriam Koopman, Cornelis J.A. Punt, C. J. Rodenburg, Ninja Antonini, Linda Mol, Otilia Dalesio, Harm Sinnige, Annemieke Cats, Allert H. Vos and Jolanda Schrama and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Frans Erdkamp

80 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

2009 1.0k citations Jolien Tol, Miriam Koopman et al. profile →
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Howard A. Burris, Mario Campone et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frans Erdkamp Netherlands	26	2.7k	1.3k	587	572	562	82	3.7k
Jean‐François Morère France	31	2.5k 0.9×	1.3k 1.0×	753 1.3×	666 1.2×	581 1.0×	216	4.0k
Sharlene Gill Canada	34	3.5k 1.3×	1.1k 0.9×	1.1k 1.8×	774 1.4×	880 1.6×	208	4.9k
Jolanda Schrama Netherlands	12	1.8k 0.7×	667 0.5×	370 0.6×	346 0.6×	431 0.8×	16	2.3k
Luigi Manzione Italy	29	2.4k 0.9×	1.3k 1.0×	267 0.5×	386 0.7×	394 0.7×	88	3.4k
Heather‐Jane Au Canada	18	2.9k 1.1×	1.2k 0.9×	1.0k 1.7×	728 1.3×	751 1.3×	29	3.9k
Francesco Di Costanzo Italy	32	3.5k 1.3×	2.4k 1.8×	541 0.9×	715 1.3×	690 1.2×	167	5.0k
Gary Richardson Australia	19	2.6k 1.0×	1.2k 1.0×	475 0.8×	734 1.3×	429 0.8×	110	3.8k
Sheryl Koski Canada	16	3.6k 1.3×	1.4k 1.1×	527 0.9×	610 1.1×	406 0.7×	35	4.9k
Pascaline Boudou‐Rouquette France	29	1.4k 0.5×	1.2k 0.9×	318 0.5×	644 1.1×	323 0.6×	133	2.9k
Mary Cabiddu Italy	34	2.5k 0.9×	1.3k 1.0×	458 0.8×	649 1.1×	771 1.4×	78	3.9k

Countries citing papers authored by Frans Erdkamp

Since Specialization

Citations

This map shows the geographic impact of Frans Erdkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frans Erdkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frans Erdkamp more than expected).

Fields of papers citing papers by Frans Erdkamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frans Erdkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frans Erdkamp. The network helps show where Frans Erdkamp may publish in the future.

Co-authorship network of co-authors of Frans Erdkamp

This figure shows the co-authorship network connecting the top 25 collaborators of Frans Erdkamp. A scholar is included among the top collaborators of Frans Erdkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frans Erdkamp. Frans Erdkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geurts, Sandra M. E., Frans Erdkamp, Joan B. Heijns, et al.. (2024). Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry. Breast Cancer Research and Treatment. 205(2). 287–302. 3 indexed citations

Kent, Stephen B. H., Inge R. Konings, Vincent van der Noort, et al.. (2024). 352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03). Annals of Oncology. 35. S364–S364. 1 indexed citations

Vriens, Ingeborg J. H., Sanne Engelen, Frans Erdkamp, et al.. (2023). The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment. 203(2). 339–349. 4 indexed citations

Geurts, Sandra M. E., Frans Erdkamp, Joan B. Heijns, et al.. (2023). 233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry. ESMO Open. 8(1). 101421–101421. 1 indexed citations

Geurts, Sandra M. E., Frans Erdkamp, M. Wouter Dercksen, et al.. (2023). Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry. The Lancet Regional Health - Europe. 26. 100573–100573. 15 indexed citations

Geurts, Sandra M. E., Irene E.G. van Hellemond, Astrid C P Swinkels, et al.. (2023). The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. JNCI Cancer Spectrum. 7(6). 4 indexed citations

Tjan‐Heijnen, Vivianne C. G., Sandra M. E. Geurts, Ingeborg J. H. Vriens, et al.. (2023). Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial. EClinicalMedicine. 58. 101901–101901. 11 indexed citations

Geurts, Sandra M. E., Frans Erdkamp, Joan B. Heijns, et al.. (2023). Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry. Clinical Breast Cancer. 24(2). 103–111. 1 indexed citations

Lobbezoo, D.J.A., Ingeborg J. H. Vriens, Loes Kooreman, et al.. (2022). The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Research and Treatment. 192(2). 331–342. 1 indexed citations

10.

Geurts, Sandra M. E., Sander Croes, Frans Erdkamp, et al.. (2021). Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Research and Treatment. 188(2). 571–581. 7 indexed citations

11.

Geurts, Sandra M. E., Frans Erdkamp, M. Wouter Dercksen, et al.. (2021). The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry. International Journal of Cancer. 150(1). 124–131. 10 indexed citations

12.

Erdkamp, Frans, Marta López‐Yurda, Jeany M. Rademaker-Lakhai, et al.. (2020). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncologica. 59(6). 713–722. 3 indexed citations

13.

Erdkamp, Frans, et al.. (2020). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. 1 indexed citations

14.

Sonke, Gabe S., Lowell L. Hart, Mario Campone, et al.. (2017). Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment. 167(3). 659–669. 61 indexed citations

15.

May, Anne M., Miranda J. Velthuis, Elsken van der Wall, et al.. (2017). Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study. BMJ Open. 7(3). e012187–e012187. 43 indexed citations

16.

Bos, Monique E.M.M., Marta López‐Yurda, A.H. Honkoop, et al.. (2017). Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG). Annals of Oncology. 28. v78–v79. 1 indexed citations

17.

Elias, Sjoerd G., Harm van Tinteren, Miangela M. Laclé, et al.. (2017). Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Annals of Oncology. 28(9). 2128–2134. 56 indexed citations

18.

Drooger, Jan C., Harm van Tinteren, Albert J. ten Tije, et al.. (2016). A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial. Cancer. 122(19). 2961–2970. 3 indexed citations

19.

Krzemieniecki, Krzysztof, P. Sevelda, Frans Erdkamp, et al.. (2013). Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice. Supportive Care in Cancer. 22(3). 667–677. 25 indexed citations

20.

Derikx, Joep P. M., Frans Erdkamp, & A. G. M. Hoofwijk. (2013). [The electronic health record: computerised provider order entry and the electronic instruction document as new functionalities].. PubMed. 157(34). A5695–A5695. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact